MyBioSource
 | |
| Company type | Public |
|---|---|
| Industry | Biotech, Life Sciences, Manufacturing |
| Founded | 2007 in Vancouver, Canada |
| Headquarters | , United States |
Area served | Worldwide |
Number of employees | 25–30 |
| Website | www |
MyBioSource, Inc. is a biotechnological products distribution company formed to create a large portfolio of laboratory research reagents, both hard to find and common items, with worldwide distributions. Backed by a network of laboratories and manufacturers, the company was launched in 2007 in Vancouver, British Columbia, Canada. Headquarters and operations were relocated to San Diego, United States.
Products
[edit]The company distributes a number of science reagents and assay kits, including custom recombinant proteins and antibodies, real time PCR and quantitative ELISA kits. The company's current catalog lists over 1 million individual products used in academic, biotechnological, and pharmaceutical industries.
Peer reviews
[edit]One peer-reviewed article[1] that compared the specificity of several, commercially-available kits for glucagon and oxyntomodulin found that the MyBioSource assay (MBS701592) for detecting oxyntomodulin "yielded inconsistent results". And another article[2] investigated the specificity of commercially available EIA kits for identification of neutralizing antibodies to adenovirus Ad36 found that "all seronegative samples (as determined by SNA) were false positive" by MyBioSource's Ad36 EIA (MBS705802).
Publications with MyBioSource products
[edit]- Bak, M. J., Albrechtsen, N. W., Pedersen, J., Hartmann, B., Christensen, M., Vilsboll, T., Knop, F. K., Deacon, C. F., Dragsted, L. O., Holst, J. J. (2014) Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. Eur J Endocrinology 170, 529–538[3]
- Dubuisson, O., Day, R. S., Dhurandhar, N. V. (2015) Accurate identification of neutralizing antibodies to adenovirus Ad36, -a putative contributor of obesity in humans. J Diabetes Complications 29, 83–87[4]
References
[edit]- ^ Bak, Monica (April 2014). "Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans". European Journal of Endocrinology. 170 (4): 529–538. doi:10.1530/EJE-13-0941. PMID 24412928. Retrieved December 9, 2021.
- ^ Dubuisson, Olga (January–February 2015). "Accurate identification of neutralizing antibodies to adenovirus Ad36, -a putative contributor of obesity in humans". Journal of Diabetes and Its Complications. 29 (1): 83–87. doi:10.1016/j.jdiacomp.2014.09.004. PMID 25312598. Retrieved December 9, 2021.
- ^ Bak, Monica (April 2014). "Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans". European Journal of Endocrinology. 170 (4): 529–538. doi:10.1530/EJE-13-0941. PMID 24412928. Retrieved December 9, 2021.
- ^ Dubuisson, Olga (January–February 2015). "Accurate identification of neutralizing antibodies to adenovirus Ad36, -a putative contributor of obesity in humans". Journal of Diabetes and Its Complications. 29 (1): 83–87. doi:10.1016/j.jdiacomp.2014.09.004. PMID 25312598. Retrieved December 9, 2021.